Compare CSX Corporation (CSX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Gilead Sciences, Inc. — how do they compare? CSX Corporation trades at $49.9 (market cap $92.55B), while Gilead Sciences, Inc. trades at $136.41 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| CSX | GILD | |
|---|---|---|
Market Cap | $92.55B | $168.35B |
Sector | Industrials | Health |
52-Week High | $53.21 | $155.80 |
52-Week Low | $32.05 | $110.56 |
Enterprise Value | $110.52B | $191.42B |
Dividend Yield | 1.12% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.12, down 0.3% on the day, with a neutral technical signal. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and margin expansion. The stock's valuation ratios, including a P/E of 29.05 and P/S of 6.41, reflect a premium pricing relative to historical levels. Analyst consensus is bullish with a $52.57 price target, supported by 58.69% buy ratings.
The outlook for CSX is positive, with projected 2026 revenue growth and improved cash flow. Key opportunities include strong intermodal demand and operational efficiency gains. Risks involve competitive pressures, fuel cost volatility, and potential economic slowdowns affecting freight volumes. The stock's current level offers a moderate upside to the consensus target, balanced by elevated valuation multiples.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
